Project Grant HT94252310350
Award Date
8/1/23
Completion Date
7/31/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The U.S. Defense Health Agency awarded a $1,626,932.00 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on March 1, 2025, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the grant will fund the "Detection and Quantification of Early Motor...
The Defense Health Agency awarded Massachusetts General Hospital a $368,238 project grant under the Military Medical Research and Development program (CFDA 12.420) from September 1, 2023 through August 31, 2026. The grant will fund research to determine if microbiome-derived cell fragments in the brain accelerate transition from traumatic brain injury to Alzheimer's disease or related dementias. As a leading academic medical center, Massachusetts General Hospital will leverage its expertise in...
The Department of Defense's Defense Health Agency awarded a $992,302 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, which runs from September 15, 2025 to September 14, 2028, will support research aimed at "Targeting MHCII Ubiquitination to Induce Immune Regulation in Vascularized Composite Tissue Transplantation." MGH, a renowned non-profit...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,234,505.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award supports research to cotarget the tumor microenvironment and revolutionize antibody-drug conjugate...
The U.S. Department of Defense (DoD) awarded a $334,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), on September 15, 2023. The award supports a 2-year research project titled "TARGETING THE NF-KB PATHWAY TO TREAT NF1-DEFICIENT TUMORS." Through this funding, MGH will conduct biomedical research to investigate novel approaches for treating tumors caused...
The Defense Health Agency awarded a $1,621,712 Project Grant to The General Hospital Corporation's Research Management Division, operating as Massachusetts General Hospital (MGH), for the "THERAPEUTIC TARGETING OF CHEMORESISTANT RHABDOMYOSARCOMA" project. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research initiatives to improve health outcomes for military service members, veterans, and the...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,644,309 project grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct advanced biomedical research focused on "FUNCTIONAL MOLECULAR NETWORKS MODIFYING HIF2A ACTIVITY IN VHL TUMORS". The grant, awarded on February 1, 2025, will support MGH's innovative research efforts to transform healthcare for military service members,...
This $334,000 Project Grant award from the Department of Defense (DOD) Defense Health Agency supports research by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to analyze extracellular vesicles in exhaled breath condensates for the diagnosis and monitoring of pulmonary fibrosis. The research project, funded under the DOD's Military Medical Research and Development program (CFDA 12.420), aims to develop improved diagnostic and monitoring capabilities...
The Defense Health Agency awarded $603,000 to the Massachusetts General Hospital under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "CLINICAL AND MRI PREDICTORS OF INTERNAL NEUROFIBROMA GROWTH IN NEUROFIBROMATOSIS TYPE 1" from September 30, 2021 through September 29, 2024. This project grant will fund research at Massachusetts General Hospital to investigate clinical and MRI predictors of internal neurofibroma growth in...
The General Hospital Corporation, doing business as Massachusetts General Hospital, received a $587,117 project grant from the Defense Health Agency's Military Medical Research and Development program to develop an online platform promoting evidence-based care for patients with neurofibromatosis 1. The three-year grant, awarded June 1, 2023 and set to be completed by May 31, 2026, aims to address medical and social barriers to care through tailoring an online resource to provide specialized...